Bioclavis
Over £10m
investment
40
jobs created
£4.5m
grant from Scottish Enterprise
In 2017, California-based life sciences company BioSpyder Technologies created a new subsidiary, BioClavis, a Glasgow-based spin-out, to adapt BioSpyder’s technology into a diagnostic tool for precision medicine.
BioSpyder invested over £10m to create BioClavis supported with a £4.5m grant from Scottish Enterprise to create 40 jobs in its new location at the Queen Elizabeth University Hospital.
Motives for chosing Glasgow:
- Government support
- Proximity to markets or customers
- Universities & Research hubs
"We determined Glasgow, Scotland to be the ideal location for this initiative based in large part on the support and close working relationships with Scottish Enterprise, the National Health Service and the University of Glasgow."
– Joel McComb, Chief Executive Officer
